The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
Abstract
Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in humans have demonstrated that islet amyloid is associated with loss of beta-cell mass, but a direct role for amyloid in the pathogenesis of type 2 diabetes cannot be inferred from such studies. Animal studies in both spontaneous and transgenic models of islet amyloid formation have shown that amyloid forms in islets before fasting hyperglycemia and therefore does not arise merely as a result of the diabetic state. Furthermore, the extent of amyloid deposition is associated with both loss of beta-cell mass and impairment in insulin secretion and glucose metabolism, suggesting a causative role for islet amyloid in the islet lesion of type 2 diabetes. These animal studies have also shown that beta-cell dysfunction seems to be an important prerequisite for islet amyloid formation, with increased secretory demand from obesity and/or insulin resistance acting to further increase islet amyloid deposition. Recent in vitro studies suggest that the cytotoxic species responsible for islet amyloid-induced beta-cell death are formed during the very early stages of islet amyloid formation, when islet amyloid polypeptide aggregation commences. Interventions to prevent islet amyloid formation are emerging, with peptide and small molecule inhibitors being developed. These agents could thus lead to a preservation of beta-cell mass and amelioration of the islet lesion in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–219 of 219
Westermark, G. T., Arora, M. B., Fox, N. W., Carroll, R., Chan, S. J., Westermark, P., & Steiner, D. F. (1995) · PubMed Central · Cited by 36
Self-citationMa, Z., & Westermark, G. (2002) · Molecular Medicine · doi:10.1007/bf03402092 · Cited by 35
Self-citationOophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes
Kahn, S. E., Andrikopoulos, S., Verchere, C. B., Wang, F., Hull, R. L., & Vidal, J. (2000) · Diabetologia · doi:10.1007/s001250051527 · Cited by 35
Self-citationMäkimattila, S., Fineman, M. S., & Yki‐Järvinen, H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6721 · Cited by 34
Aiyar, N. V., Baker, E., Martin, J. R., Patel, A., Stadel, J. M., Willette, R. N., & Barone, F. C. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031131.x · Cited by 33
Effect of Glucocorticoid and Growth Hormone Treatment on Proinsulin Levels in Humans
Kahn, S. E., Horber, F., Prigeon, R. L., Haymond, M. W., & Porte, D. (1993) · Diabetes · doi:10.2337/diab.42.7.1082 · Cited by 31
Self-citationMa, Z., Westermark, G. T., Johnson, K. H., Brien, T. D. O., & Westermark, P. (1998) · Amyloid · doi:10.3109/13506129809007298 · Cited by 31
Self-citationVidal, J., Verchere, C. B., Andrikopoulos, S., Wang, F., Hull, R. L., Cnop, M., Olin, K., LeBoeuf, R. C., O’Brien, K. D., Chait, A., et al. (2003) · Diabetologia · doi:10.1007/s00125-002-0984-5 · Cited by 30
Self-citationVerchere, C. B., D’Alessio, D. A., Palmiter, R. D., & Kahn, S. E. (1994) · Diabetologia · doi:10.1007/bf00417699 · Cited by 29
Self-citationRenal Elimination of Islet Amyloid Polypeptide
Leckström, A., Björklund, K., Permert, J., Larsson, R., & Westermark, P. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7465 · Cited by 29
Self-citationGlucose Stimulates and Potentiates Islet Amyloid Polypeptide Secretion by the B-Cell
Kahn, S., Fujimoto, W., D'Alessio, D., Ensinck, J., & Porte, D. (1991) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003759 · Cited by 28
Self-citationNovel Glycosaminoglycan Precursors as Antiamyloid Agents: Part IV
Kisilevsky, R., Szarek, W. A., Ancsin, J. B., Vohra, R., Li, Z., & Marone, S. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:167 · Cited by 28
Inamdar, P., Kelkar, S. M., Devasagayam, T. P. A., & Bapat, M. M. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00126-6 · Cited by 26
Arnelo, U., Herrington, M. K., Theodorsson, E., Adrian, T. E., Reidelberger, R. D., Larsson, J., Marcusson, J., Strömmer, L., Ding, X., & Permert, J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)03070-5 · Cited by 22
Makimattila, S. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2822 · Cited by 21
Hall, J. M., & Brain, S. D. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702272 · Cited by 20
Ma, Z., Westermark, G. T., Li, Z.-C., Engström, U., & Westermark, P. (1997) · Diabetologia · doi:10.1007/s001250050751 · Cited by 18
Self-citationEto, M., Watanabe, K., Makino, I., & Ishii, K. (1991) · Metabolism · doi:10.1016/0026-0495(91)90002-e · Cited by 18
Zapecka-Dubno, B., Czyiyk, A., Dworak, A., & Bak, M. I. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300423 · Cited by 13
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
Self-citationProtein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O'Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 762
Metadata
- Authors
- Hull, R. L., Westermark, G. T., Westermark, P., & Kahn, S. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-08
- Volume
- 89
- Issue
- 8
- Pages
- 3629-3643
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2136989779
- Cited by
- 583
- References
- 219
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.